Ernexa Therapeutics (NASDAQ:ERNA) Announces Quarterly Earnings Results

Ernexa Therapeutics (NASDAQ:ERNA) posted its earnings results on Friday. The company reported ($1.89) earnings per share for the quarter, beating the consensus estimate of ($3.84) by $1.95, Zacks reports.

Ernexa Therapeutics Stock Performance

Shares of NASDAQ:ERNA opened at $1.87 on Friday. The company has a 50-day simple moving average of $3.01 and a 200-day simple moving average of $6.91. Ernexa Therapeutics has a one year low of $1.74 and a one year high of $46.11. The stock has a market capitalization of $3.05 million, a price-to-earnings ratio of -0.15 and a beta of 2.75.

Analyst Upgrades and Downgrades

ERNA has been the topic of several research analyst reports. Wall Street Zen lowered Ernexa Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. Weiss Ratings reissued a “sell (e+)” rating on shares of Ernexa Therapeutics in a report on Thursday, October 15th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $30.00.

Ernexa Therapeutics Company Profile

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc was founded in 2018 and is based in Cambridge, Massachusetts.